Healthline/1m ago
FDA Approves Lilly’s New Oral Combo Pill for Common Breast Cancer Mutation
FDA Approves Lilly’s New Oral Combo Pill for Common Breast Cancer Mutation. The Eli Lilly corporate headquarters in Indianapolis, IN, on August 15, 2024. AJ Mast/Bloomberg via Getty Images The FDA approved a new oral combo drug for a common breast cancer mutation on September 18. The treatment includes Inluriyo (imlunestrant) taken with Verzenio (abemaciclib) for adults with ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutation that has spread after hormone therapy. Results from a trial show that among 159 participants with ESR1 mutations, those taking the combination went a median of 11.1 months before their cancer spread,.